Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.
Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.